| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $28.5M | +62.7% |
| SG&A Expense | $13.6M | +16.2% |
| Operating Income | -$42.0M | -44.1% |
| Income Tax | $0 | — |
| Net Income | -$41.8M | -41.9% |
| EPS (Basic) | -$1.50 | +21.5% |
| EPS (Diluted) | -$1.50 | +21.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $30.3M | -22.8% |
| Current Assets | $31.5M | -22.0% |
| Total Assets | $41.5M | -19.6% |
| Current Liabilities | $14.2M | +51.1% |
| Long-term Debt | $6.4M | -39.0% |
| Total Liabilities | $22.4M | -10.0% |
| Stockholders' Equity | $19.1M | -28.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$33.0M | -20.7% |
| Capital Expenditures | $435K | +155.9% |
| Investing Cash Flow | -$435K | -155.9% |
| Financing Cash Flow | $24.5M | -31.2% |
| Free Cash Flow | -$33.5M | -21.6% |